FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a study in Cancers1 demonstrating that DecisionDx-Melanoma provided significantly better risk stratification than American Joint Committee on Cancer 8th Edition (AJCC8) staging in patients with stage I cutaneous melanoma (CM). This study reports the results of two large stage I cohorts, including 5,651 patients from the ...

FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the fourth quarter and year ended Dec. 31, 2023, after the close of market on Wednesday, Feb. 28, 2024. Company management will host a conference call and webcast to discuss its financial results at 4:30 p.m. Eastern time on the same day. Conference Call and Webcast Details A live webcast o ...

FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a new study1 in The Journal of Clinical and Aesthetic Dermatology (JCAD) which found that using its DecisionDx-SCC test to guide ART decisions for patients with SCC could result in substantial Medicare healthcare savings of up to approximately $972 million annually. “The implications of this study are significant, as ...

FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will present new data across its dermatologic portfolio of commercially available and pipeline gene expression profile (GEP) tests at the 2024 Winter Clinical Dermatology Conference - Hawaii, being held Jan. 12-17 in Honolulu, Hawaii. “We are committed to challenging current disease management paradigms and building the evidence supporting our portfoli ...

FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its Chief Operating Officer, Kristen Oelschlager, has been named to The Healthcare Technology Report’s Top 25 Women Leaders in Biotechnology of 2023. The honorees “stand as a driving force, ensuring diverse perspectives on scientific breakthroughs and groundbreaking therapies,” according to the publication. “Their achievements serve a ...

FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced certain unaudited preliminary performance results for the fourth quarter and year ended Dec. 31, 2023. “Our fourth quarter was the culmination of an exceptional year, where we delivered consistent, strong growth in both revenue and test volume,” said Derek Maetzold, president and chief executive officer of Castle Biosciences. “Our perfo ...

Castle Biosciences, Inc. (NASDAQ:CSTL) Q3 2023 Earnings Conference Call November 2, 2023 4:30 PM ET Company Participants Camilla Zuckero - Vice President, Investor Relations and Corporate Affairs Derek Maetzold - Founder, President and Chief Executive Officer Frank Stokes - Chief Financial Officer Conference Call Participants Thomas Flaten - Lake Street Puneet Souda - Leerink Partners Catherine Schulte - Baird Mason Carrico - Stephens Mark Massaro - BTIG Operator Good afternoon and welcome to Castle Bioscie ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ (State or other jurisdiction of incorporation or organization) 505 S. Friendswood Drive, Suite 401, Friendswood, ...

Castle Biosciences, Inc. (NASDAQ:CSTL) Q2 2023 Earnings Conference Call August 2, 2023 4:30 PM ET Company Participants Camilla Zuckero - Vice President, Investor Relations & Corporate Affairs Derek Maetzold - Founder, President & Chief Executive Officer Frank Stokes - Chief Financial Officer Conference Call Participants Carl Nixon - Canacord Sung Ji Nam - Scotiabank Thomas Flaten - Lake Street Capital Markets Puneet Souda - SVB Mason Carrick - Stevens Catherine Schulte - Baird Mark Massaro - BTIG Operator G ...

34 Table of Contents The following table provides a disaggregation of net revenues by type (in thousands): | --- | --- | --- | --- | --- | --- | --- | --- | |------------------------|-------|-------|-------------------------|------------------------|--------|-------|--------| | | | | Six Months Ended \n2023 | June 30, \n(unaudited) | 2022 | | Change | | (1) Dermatologic | | $ | 78,941 | $ | 56,236 | $ | 22,705 | | (2) Non-Dermatologic | | | 13,234 | | 5,454 | | 7,780 | | Total net revenues | | $ | 92,175 | ...